Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:

NCT04726553 is registered in ClinicalTrials.gov with Oklahoma Medical Research Foundation as lead sponsor.

NCT NCT04726553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04726553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:
Lead sponsor
Oklahoma Medical Research Foundation
Phase
Phase 1
Overall status
Unknown status
Start date
January 20, 2021
Completion date
December 31, 2024
Enrollment
20 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)